Indication expansion

New Buck Institute study is treasure trove for longevity research

Indication expansion

Gerostate Alpha: “Our phenotype is lifespan”

Indication expansion

Drusolv targets macular degeneration with statin therapy

Drusolv seeks $2 million to prepare IND application for repurposed statin for treatment of AMD ahead of Phase 2 trials.
Indication expansion

“The major modulators of aging remain to be discovered”

Indication expansion

A year in Longevity: progress perspectives

Indication expansion

A year in Longevity: different perspectives

Indication expansion

Longevity biomarker firm to align CROs, pharma and consumers

Indication expansion

Eliminating senescent cells to improve heart attack recovery

Indication expansion

Calico’s memory-enhancing drug reverses age-related mental decline

Indication expansion

BioAge CEO: “It’s all about the data.”

Indication expansion

BioAge lands $90 million; gears up for clinical trials in 2021

Indication expansion

AgelessRx and funding an IRB-approved rapamycin trial

Indication expansion

COVID-19: Leading clinician calls for focus on the biology of aging

Indication expansion

Inflammaging – could ibuprofen be the answer?

Indication expansion

Peptide molecule causes cancer cells to self destruct

Indication expansion

Using small data to target Alzheimer’s

Indication expansion

Combining existing medicines to target aging

Indication expansion

Reproductive Longevity – taking the geroscience approach

Indication expansion

Longevity-extending compounds key to neurodegenerative treatment

Indication expansion

The metformin debate swings both ways

Indication expansion

$2m Longevity boost for rapamycin Alzheimer’s study

Indication expansion

GlobalData finds AI accelerates drug repurposing

Indication expansion

FDA approval for small molecule drug bodes well for Longevity

Indication expansion

Fruit fly research could hold key to lifespan

Indication expansion

Exploring the neuroprotective benefits of Longevity drug candidates

Indication expansion

Challenging the one drug/one disease model

Indication expansion

Fountain’s ‘hypothesis-free’ approach to Longevity AI

Indication expansion

Applying theoretical physics to Longevity drug discovery

Indication expansion

Longevity and the art of motorcycle maintenance

Indication expansion

BioAge licenses HIF-PH inhibitor to treat aging

Indication expansion

Longevity2020: Day 3 recap

Indication expansion

Building faster and better age-related clinical trials

Indication expansion